MINIMAL RESIDUAL DISEASE
Clinical trials for MINIMAL RESIDUAL DISEASE explained in plain language.
Never miss a new study
Get alerted when new MINIMAL RESIDUAL DISEASE trials appear
Sign up with your email to follow new studies for MINIMAL RESIDUAL DISEASE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New stem cell transplant could reduce dangerous side effects in blood cancer patients
Disease control Recruiting nowThis study tests a new type of stem cell transplant for children and adults with blood cancers like leukemia. The transplant uses a special process to remove certain immune cells, aiming to lower the risk of graft-versus-host disease (a serious complication where donor cells atta…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Disease control
Last updated May 01, 2026 14:32 UTC
-
Engineered immune cells take aim at lingering colorectal cancer
Disease control Recruiting nowThis early-phase trial tests a new treatment for people with colorectal cancer who have minimal residual disease (tiny amounts of cancer left after treatment). The therapy uses specially engineered natural killer (NK) cells from donated cord blood, designed to target a protein ca…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:52 UTC
-
New combo aims to wipe out hidden colorectal cancer cells
Disease control Recruiting nowThis study tests whether two drugs, fruquintinib and tislelizumab, can control leftover cancer cells in people with colorectal cancer who have completed chemotherapy but still show signs of minimal residual disease (MRD) on a blood test. About 20 adults with stable disease will r…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Apr 30, 2026 15:51 UTC
-
Engineered immune cells take aim at returning leukemia after transplant
Disease control Recruiting nowThis early-stage study tests a new treatment for children and adults whose acute leukemia has come back or not responded after a donor stem cell transplant. The treatment uses specially engineered immune cells (T cells) from the original donor that are trained to recognize and at…
Matched conditions: MINIMAL RESIDUAL DISEASE
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Apr 29, 2026 15:04 UTC